Arterial stiffness and inflammation - A potential target for a drug therapy

Artery Research

Volumn 4, Issue 4, 2010, Pages 99-107

  Mäki Petäjä, Kaisa M ^a   Wilkinson, Ian B ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Anti inflammatory therapy; Arterial stiffness; Inflammation; Rheumatoid arthritis; Statins

Indexed keywords

AMLODIPINE; ANTIINFLAMMATORY AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ELASTIN; ENDOTHELIN 1; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; MATRIX METALLOPROTEINASE; METHOTREXATE; NITRIC OXIDE; PITAVASTATIN; PRAVASTATIN; PROBUCOL; ROFECOXIB; ROSUVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTERIAL STIFFNESS; BEHCET DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORTICOSTEROID THERAPY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG TARGETING; DYSLIPIDEMIA; EXTRACELLULAR MATRIX; FAMILIAL HYPERCHOLESTEROLEMIA; FIBRINOLYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; HYPOTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PULSE PRESSURE; PULSE WAVE; RHEUMATOID ARTHRITIS; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; THROMBOSIS;

EID: 78649854786     PISSN: 18729312     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.artres.2010.10.002     Document Type: Short Survey

References (113)

1. Libby P. Inflammation in atherosclerosis. Nature 2002 December 19, 420:868-874.
2. Liuzzo G., Biasucci L.M., Gallimore J.R., Grillo R.L., Rebuzzi A.G., Pepys M.B., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994 August 18, 331:417-424.
3. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002 November 14, 347:1557-1565.
4. Wolfe F., Mitchell D.M., Sibley J.T., Fries J.F., Bloch D.A., Williams C.A., et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994 April, 37:481-494.
5. Van Doornum S., McColl G., Wicks I.P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?. Arthritis Rheum 2002 April, 46:862-873.
6. del Rincon I.D., Williams K., Stern M.P., Freeman G.L., Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001 December, 44:2737-2745.
7. Symmons D.P., Jones M.A., Scott D.L., Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998 June, 25:1072-1077.
8. Pasceri V., Yeh E.T. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999 November 23, 100:2124-2126.
9. Blacher J., Guerin A.P., Pannier B., Marchais S.J., Safar M.E., London G.M. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999 May 11, 99:2434-2439.
10. Willum-Hansen T., Staessen J.A., Torp-Pedersen C., Rasmussen S., Thijs L., Ibsen H., et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006 February 7, 113:664-670.
11. Laurent S., Boutouyrie P., Asmar R., Gautier I., Laloux B., Guize L., et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001 May, 37:1236-1241.
12. Cruickshank K., Riste L., Anderson S.G., Wright J.S., Dunn G., Gosling R.G. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?. Circulation 2002 October 15, 106:2085-2090.
13. Zieman S.J., Melenovsky V., Kass D.A. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005 May, 25:932-943.
14. Nichols W.W. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005 January, 18:3S-10S.
15. O'Rourke M.F., Nichols W.W. Aortic diameter, aortic stiffness, and wave reflection increase with age and isolated systolic hypertension. Hypertension 2005 April, 45:652-658.
16. Schmitt M., Avolio A., Qasem A., Mceniery C.M., Butlin M., Wilkinson I.B., et al. Basal NO locally modulates human iliac artery function in vivo. Hypertension 2005 July, 46:227-231.
17. Mceniery C.M., Wallace S., Mackenzie I.S., McDonnell B., Yasmin, Newby D.E., et al. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension 2006 October, 48:602-608.
18. Mceniery C.M., Spratt M., Munnery M., Yarnell J., Lowe G.D., Rumley A., et al. An analysis of prospective risk factors for aortic stiffness in men: 20-year follow-up from the Caerphilly prospective study. Hypertension 2010 July, 56:36-43.
19. Wilkinson I.B., Mceniery C.M. Arterial stiffness, endothelial function and novel pharmacological approaches. Clin Exp Pharmacol Physiol 2004 November, 31:795-799.
20. Laurent S., Cockcroft J., Van Bortel L., Boutouyrie P., Giannattasio C., Hayoz D., et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006 November, 27:2588-2605.
21. Currie C.J., Poole C.D., Conway P. Evaluation of the association between the first observation and the longitudinal change in C-reactive protein, and all-cause mortality. Heart 2008 April, 94:457-462.
22. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000 March 23, 342:836-843.
23. Kampus P., Kals J., Ristimae T., Muda P., Ulst K., Zilmer K., et al. Augmentation index and carotid intima-media thickness are differently related to age, C-reactive protein and oxidized low-density lipoprotein. J Hypertens 2007 April, 25:819-825.
24. Yasmin, Mceniery C.M., Wallace S., Mackenzie I.S., Cockcroft J.R., Wilkinson I.B. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 2004 May, 24:969-974.
25. Schumacher W., Cockcroft J., Timpson N.J., Mceniery C.M., Gallacher J., Rumley A., et al. Association between C-reactive protein genotype, circulating levels, and aortic pulse wave velocity. Hypertension 2009 February, 53:150-157.
26. Elliott P., Chambers J.C., Zhang W., Clarke R., Hopewell J.C., Peden J.F., et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009 July 1, 302:37-48.
27. Vlachopoulos C., Dima I., Aznaouridis K., Vasiliadou C., Ioakeimidis N., Aggeli C., et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 2005 October 4, 112:2193-2200.
28. Wallberg-Jonsson S., Johansson H., Ohman M.L., Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999 December, 26:2562-2571.
29. Manzi S., Meilahn E.N., Rairie J.E., Conte C.G., Medsger T.A., Jansen-McWilliams L., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997 March 1, 145:408-415.
30. Wallberg-Jonsson S., Caidahl K., Klintland N., Nyberg G., Rantapaa-Dahlqvist S. Increased arterial stiffness and indication of endothelial dysfunction in long-standing rheumatoid arthritis. Scand J Rheumatol 2008 January, 37:1-5.
31. Maki-Petaja K.M., Hall F.C., Booth A.D., Wallace S.M., Yasmin, Bearcroft P.W., et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006 September 12, 114:1185-1192.
32. Klocke R., Cockcroft J.R., Taylor G.J., Hall I.R., Blake D.R. Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. Ann Rheum Dis 2003 May, 62:414-418.
33. Turesson C., Jacobsson L., Ryden A.A., Sturfelt G., Wollmer P., Lanne T. Increased stiffness of the abdominal aorta in women with rheumatoid arthritis. Rheumatology (Oxford) 2005 March 22, 44:896-901.
34. Roman M.J., Devereux R.B., Schwartz J.E., Lockshin M.D., Paget S.A., Davis A., et al. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005 May 23, 46:1-6.
35. Wong M., Toh L., Wilson A., Rowley K., Karschimkus C., Prior D., et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003 January, 48:81-89.
36. Van Doornum S., McColl G., Jenkins A., Green D.J., Wicks I.P. Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 2003 January, 48:72-80.
37. Holmes M.V., Jiang B., McNeill K., Wong M., Oakley S.P., Kirkham B., et al. Paradoxical association of C-reactive protein with endothelial function in rheumatoid arthritis. PLoS One 2010, 5:e10242.
38. Booth A.D., Wallace S., Mceniery C.M., Yasmin, Brown J., Jayne D.R., et al. Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis Rheum 2004 February, 50:581-588.
39. Ng W.F., Fantin F., Ng C., Dockery F., Schiff R., Davies K.A., et al. Takayasu's arteritis: a cause of prolonged arterial stiffness. Rheumatology (Oxford) 2006 June, 45:741-745.
40. Yildiz M. Arterial distensibility in chronic inflammatory rheumatic disorders. Open Cardiovasc Med J 2010, 4:83-88.
41. Maxwell S.R., Moots R.J., Kendall M.J. Corticosteroids: do they damage the cardiovascular system?. Postgrad Med J 1994 December, 70:863-870.
42. Slot O. Changes in plasma homocysteine in arthritis patients starting treatment with low-dose methotrexate subsequently supplemented with folic acid. Scand J Rheumatol 2001, 30:305-307.
43. Reicin A.S., Shapiro D., Sperling R.S., Barr E., Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 2002 January 15, 89:204-209.
44. Gislason G.H., Jacobsen S., Rasmussen J.N., Rasmussen S., Buch P., Friberg J., et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006 June 27, 113:2906-2913.
45. Nussmeier N.A., Whelton A.A., Brown M.T., Langford R.M., Hoeft A., Parlow J.L., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005 March 17, 352:1081-1091.
46. Protogerou A.D., Lekakis J., Ikonomidis I., Stamatelopoulos K., Aznaouridis K., Karatzis E.N., et al. Pressure wave reflections, central blood pressure, and aortic stiffness in patients with Adamantiades-Behcet's disease: a cross-sectional case-control study underlining the role of chronic corticosteroid treatment. Am J Hypertens 2006 July, 19:660-666.
47. Pieringer H., Stuby U., Hargassner S., Biesenbach G. Treatment with corticosteroids reduces arterial stiffness in patients with polymyalgia rheumatica as measured with pulse wave analysis. Ann Rheum Dis 2008 February, 67:279.
48. Wong M., Jiang B.Y., McNeill K., Farish S., Kirkham B., Chowienczyk P. Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis. Scand J Rheumatol 2007 July, 36:265-269.
49. Angel K., Provan S.A., Gulseth H.L., Mowinckel P., Kvien T.K., Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010 February, 55:333-338.
50. Cypiene A., Laucevicius A., Venalis A., Ryliskyte L., Dadoniene J., Petrulioniene Z., et al. Non-invasive assessment of arterial stiffness indices by applanation tonometry and pulse wave analysis in patients with rheumatoid arthritis treated with TNF-alpha blocker remicade (infliximab). Proc West Pharmacol Soc 2007, 50:119-122.
51. Galarraga B., Khan F., Kumar P., Pullar T., Belch J.J. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2009 November, 48:1418-1423.
52. Doornum S.V., McColl G., Wicks I.P. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2005 August 2, 44:1428-1432.
53. Pieringer H., Stuby U., Pohanka E., Biesenbach G. Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with infliximab. Clin Rheumatol 2010 July, 29:723-727.
54. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997 March 4, 95:1126-1131.
55. Martinez-Gonzalez J., Raposo B., Rodriguez C., Badimon L. 3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation. Arterioscler Thromb Vasc Biol 2001 May, 21:804-809.
56. Feron O., Dessy C., Desager J.P., Balligand J.L. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001 January 2, 103:113-118.
57. Suzumura K., Yasuhara M., Tanaka K., Suzuki T. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. Biochem Pharmacol 1999 March 15, 57:697-703.
58. McCarey D.W., McInnes I.B., Madhok R., Hampson R., Scherbakov O., Ford I., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004 June 19, 363:2015-2021.
59. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000 December, 6:1399-1402.
60. Tomochika Y., Okuda F., Tanaka N., Wasaki Y., Tokisawa I., Aoyagi S., et al. Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol-lowering therapies in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996 August, 16:955-962.
61. Muramatsu J., Kobayashi A., Hasegawa N., Yokouchi S. Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin. Atherosclerosis 1997 April, 130:179-182.
62. Yokoyama H., Kawasaki M., Ito Y., Minatoguchi S., Fujiwara H. Effects of fluvastatin on the carotid arterial media as assessed by integrated backscatter ultrasound compared with pulse-wave velocity. J Am Coll Cardiol 2005 December 6, 46:2031-2037.
63. Senzaki H., Chen C.H., Ishido H., Masutani S., Matsunaga T., Taketazu M., et al. Arterial hemodynamics in patients after Kawasaki disease. Circulation 2005 April 26, 111:2119-2125.
64. Cheung Y.F., Ho M.H., Tam S.C., Yung T.C. Increased high sensitivity C reactive protein concentrations and increased arterial stiffness in children with a history of Kawasaki disease. Heart 2004 November, 90:1281-1285.
65. Rheumatoid vasculitis 2007, Johns Hopkins Vasculitis Centre, Ref Type: Internet Communication. http://vasculitis.med.jhu.edu/types/rheumatoid.html.
66. Watts R.A., Carruthers D.M., Symmons D.P., Scott D.G. The incidence of rheumatoid vasculitis in the Norwich Health Authority. Br J Rheumatol 1994 September, 33:832-833.
67. Watts R.A., Mooney J., Lane S.E., Scott D.G. Rheumatoid vasculitis: becoming extinct?. Rheumatology (Oxford) 2004 July, 43:920-923.
68. Rheumatoid vasculitis 2007, The Cleveland Clinic, Ref Type: Internet Communication. http://www.clevelandclinic.org/arthritis/treat/facts/rheumatoid%20vasculitis.htm.
69. Hollan I., Prayson R., Saatvedt K., Almdahl S.M., Nossent H.C., Mikkelsen K., et al. Inflammatory cell infiltrates in vessels with different susceptibility to atherosclerosis in rheumatic and non-rheumatic patients: a controlled study of biopsy specimens obtained at coronary artery surgery. Circ J 2008 December, 72:1986-1992.
70. Floege J., Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant 2004 August, 19(Suppl. 5):V59-V66.
71. Ford M.L., Tomlinson L.A., Smith E.R., Rajkumar C., Holt S.G. Fetuin-A is an independent determinant of change of aortic stiffness over 1 year in non-diabetic patients with CKD stages 3 and 4. Nephrol Dial Transplant 2010 June, 25:1853-1858.
72. Yasmin, Wallace S., Mceniery C.M., Dakham Z., Pusalkar P., Maki-Petaja K., et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005 February, 25:372.
73. Montero I., Orbe J., Varo N., Beloqui O., Monreal J.I., Rodriguez J.A., et al. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 2006 April 4, 47:1369-1378.
74. Green M.J., Gough A.K., Devlin J., Smith J., Astin P., Taylor D., et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2003 January, 42:83-88.
75. Masuhara K., Nakai T., Yamaguchi K., Yamasaki S., Sasaguri Y. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip. Arthritis Rheum 2002 October, 46:2625-2631.
76. Yoshihara Y., Nakamura H., Obata K., Yamada H., Hayakawa T., Fujikawa K., et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000 June, 59:455-461.
77. Vlachopoulos C., Aznaouridis K., Dima I., Ioakeimidis N., Vasiliadou C., Zervoudaki A., et al. Negative association between serum levels of matrix metalloproteinases-2 and -9 and aortic stiffness in healthy adults. Int J Cardiol 2007 November 30, 122:232-238.
78. Yasmin, Mceniery C.M., O'Shaughnessy K.M., Harnett P., Arshad A., Wallace S., et al. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol 2006 August, 26:1799-1805.
79. Raines E.W. The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease. Int J Exp Pathol 2000 June, 81:173-182.
80. Toole B.P., Wight T.N., Tammi M.I. Hyaluronan-cell interactions in cancer and vascular disease. J Biol Chem 2002 February 15, 277:4593-4596.
81. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999 January 14, 340:115-126.
82. Mceniery C.M., Wilkinson I.B. Large artery stiffness and inflammation. J Hum Hypertens 2005 July, 19:507-509.
83. Cosentino F., Katusic Z.S. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 1995 January 1, 91:139-144.
84. Kinoshita H., Tsutsui M., Milstien S., Katusic Z.S. Tetrahydrobiopterin, nitric oxide and regulation of cerebral arterial tone. Prog Neurobiol 1997 July, 52:295-302.
85. Gunnett C.A., Lund D.D., McDowell A.K., Faraci F.M., Heistad D.D. Mechanisms of inducible nitric oxide synthase-mediated vascular dysfunction. Arterioscler Thromb Vasc Biol 2005 August, 25:1617-1622.
86. Vasquez-Vivar J., Kalyanaraman B., Martasek P., Hogg N., Masters B.S., Karoui H., et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 1998 August 4, 95:9220-9225.
87. Wilkinson I.B., Qasem A., Mceniery C.M., Webb D.J., Avolio A.P., Cockcroft J.R. Nitric oxide regulates local arterial distensibility in vivo. Circulation 2002 January 15, 105:213-217.
88. Smilde T.J., van den Berkmortel F.W., Wollersheim H., van Langen H., Kastelein J.J., Stalenhoef A.F. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. Eur J Clin Invest 2000 June, 30:473-480.
89. Leibovitz E., Hazanov N., Zimlichman R., Shargorodsky M., Gavish D. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens 2001 November, 14:1096-1098.
90. Shige H., Dart A., Nestel P. Simvastatin improves arterial compliance in the lower limb but not in the aorta. Atherosclerosis 2001 March, 155:245-250.
91. Ferrier K.E., Muhlmann M.H., Baguet J.P., Cameron J.D., Jennings G.L., Dart A.M., et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002 March 20, 39:1020-1025.
92. Ichihara A., Hayashi M., Ryuzaki M., Handa M., Furukawa T., Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002 August, 17:1513-1517.
93. Raison J., Rudnichi A., Safar M.E. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. J Hum Hypertens 2002 October, 16:705-710.
94. Karter Y., Curgunlu A., Erturk N., Vehid S., Mihmanli I., Ayan F. Effects of low and high doses of atorvastatin on arterial compliance. Jpn Heart J 2003 November, 44:953-961.
95. Kontopoulos A.G., Athyros V.G., Pehlivanidis A.N., Demitriadis D.S., Papageorgiou A.A., Boudoulas H. Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. Curr Med Res Opin 2003, 19:22-27.
96. Kosch M., Barenbrock M., Suwelack B., Schaefer R.M., Rahn K.H., Hausberg M. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. Am J Kidney Dis 2003 May, 41:1088-1096.
97. Leibovitz E., Beniashvili M., Zimlichman R., Freiman A., Shargorodsky M., Gavish D. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am J Hypertens 2003 September, 16:715-718.
98. Stepien J.M., Prideaux R.M., Willoughby S.R., Chirkov Y.Y., Horowitz J.D. Pilot study examining the effect of cholesterol lowering on platelet nitric oxide responsiveness and arterial stiffness in subjects with isolated mild hypercholesterolaemia. Clin Exp Pharmacol Physiol 2003 July, 30:507-512.
99. Saliashvili G., Davis W.W., Harris M.T., Le N.A., Brown W.V. Simvastatin improved arterial compliance in high-risk patients. Vasc Endovascular Surg 2004 November, 38:519-523.
100. Van Doornum S., McColl G., Wicks I.P. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2004 December, 63:1571-1575.
101. Ichihara A., Hayashi M., Koura Y., Tada Y., Kaneshiro Y., Saruta T. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens 2005 February, 19:103-109.
102. Matsuo T., Iwade K., Hirata N., Yamashita M., Ikegami H., Tanaka N., et al. Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia. Heart Vessels 2005 February, 20:8-12.
103. Shinohara K., Shoji T., Kimoto E., Yokoyama H., Fujiwara S., Hatsuda S., et al. Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2005, 12:205-210.
104. Dogra G., Irish A., Chan D., Watts G. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. Am J Kidney Dis 2007 June, 49:776-785.
105. Efrati S., Averbukh M., Dishy V., Faygenzo M., Friedensohn L., Golik A. The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur J Clin Pharmacol 2007 February, 63:113-121.
106. Maki-Petaja K.M., Booth A.D., Hall F.C., Wallace S.M., Brown J., Mceniery C.M., et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007 August 28, 50:852-858.
107. Pirro M., Schillaci G., Mannarino M.R., Savarese G., Vaudo G., Siepi D., et al. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. Nutr Metab Cardiovasc Dis 2007 July, 17:436-441.
108. Hongo M., Tsutsui H., Mawatari E., Hidaka H., Kumazaki S., Yazaki Y., et al. Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study. Circ J 2008 May, 72:722-728.
109. Mizuguchi Y., Oishi Y., Miyoshi H., Iuchi A., Nagase N., Oki T. Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia. Circ J 2008 April, 72:538-544.
110. Meng X., Qie L., Wang Y., Zhong M., Li L. Assessment of arterial stiffness affected by atorvastatin in coronary artery disease using pulse wave velocity. Clin Invest Med 2009, 32:E238.
111. Miyashita Y., Endo K., Saiki A., Ban N., Yamaguchi T., Kawana H., et al. Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb 2009 October, 16:539-545.
112. Orr J.S., Dengo A.L., Rivero J.M., Davy K.P. Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults. Hypertension 2009 October, 54:763-768.
113. Fassett R.G., Robertson I.K., Ball M.J., Geraghty D.P., Coombes J.S. Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial. Atherosclerosis 2010 August 11.